ES2401110T3 - Análisis de ácido nucleico metilado - Google Patents
Análisis de ácido nucleico metilado Download PDFInfo
- Publication number
- ES2401110T3 ES2401110T3 ES05707697T ES05707697T ES2401110T3 ES 2401110 T3 ES2401110 T3 ES 2401110T3 ES 05707697 T ES05707697 T ES 05707697T ES 05707697 T ES05707697 T ES 05707697T ES 2401110 T3 ES2401110 T3 ES 2401110T3
- Authority
- ES
- Spain
- Prior art keywords
- nucleic acid
- methylated
- sample
- acid fragments
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 135
- 108020004707 nucleic acids Proteins 0.000 title claims description 81
- 102000039446 nucleic acids Human genes 0.000 title claims description 81
- 238000004458 analytical method Methods 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 85
- 230000027455 binding Effects 0.000 claims abstract description 26
- 239000002777 nucleoside Substances 0.000 claims abstract description 24
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 23
- 108020004414 DNA Proteins 0.000 claims description 49
- 230000011987 methylation Effects 0.000 claims description 45
- 238000007069 methylation reaction Methods 0.000 claims description 45
- 108700028369 Alleles Proteins 0.000 claims description 34
- 239000012634 fragment Substances 0.000 claims description 34
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000000758 substrate Substances 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 11
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical group O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000011324 bead Substances 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000004393 prognosis Methods 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 3
- YUDSCJBUWTYENI-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]pyrimidin-2-one Chemical group C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O YUDSCJBUWTYENI-VPCXQMTMSA-N 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 13
- 230000001594 aberrant effect Effects 0.000 description 12
- 230000008775 paternal effect Effects 0.000 description 12
- 230000007067 DNA methylation Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 108091029523 CpG island Proteins 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000008774 maternal effect Effects 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 7
- 241000699658 Mus musculus domesticus Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 4
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100020856 Forkhead box protein F1 Human genes 0.000 description 4
- 101000931494 Homo sapiens Forkhead box protein F1 Proteins 0.000 description 4
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 4
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006607 hypermethylation Effects 0.000 description 4
- 125000003835 nucleoside group Chemical group 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 3
- 108091007507 ADAM12 Proteins 0.000 description 3
- 102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 101000743808 Homo sapiens Zinc finger protein 677 Proteins 0.000 description 3
- 241000699667 Mus spretus Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102100021796 Sonic hedgehog protein Human genes 0.000 description 3
- 101710113849 Sonic hedgehog protein Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 108091035715 XIST (gene) Proteins 0.000 description 3
- 102100039055 Zinc finger protein 677 Human genes 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000658654 Homo sapiens Tetratricopeptide repeat protein 23-like Proteins 0.000 description 2
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 2
- 101000781608 Homo sapiens WSC domain-containing protein 2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 108020001027 Ribosomal DNA Proteins 0.000 description 2
- 102100034910 Tetratricopeptide repeat protein 23-like Human genes 0.000 description 2
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 102100036847 WSC domain-containing protein 2 Human genes 0.000 description 2
- 108091007416 X-inactive specific transcript Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241001161843 Chandra Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150060333 GATA3 gene Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101000677110 Homo sapiens Ras-like protein family member 11A Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 102100021586 Ras-like protein family member 11A Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000025449 regulation of DNA methylation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- -1 sodium chloride Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0413688 | 2004-06-18 | ||
| GBGB0413688.3A GB0413688D0 (en) | 2004-06-18 | 2004-06-18 | Analysis of methylated nucleic acid |
| PCT/EP2005/002251 WO2005123942A2 (en) | 2004-06-18 | 2005-03-03 | Analysis of methylated nucleic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2401110T3 true ES2401110T3 (es) | 2013-04-17 |
Family
ID=32750180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05707697T Expired - Lifetime ES2401110T3 (es) | 2004-06-18 | 2005-03-03 | Análisis de ácido nucleico metilado |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20090270482A1 (enExample) |
| EP (1) | EP1761639B1 (enExample) |
| JP (1) | JP2008502332A (enExample) |
| AU (2) | AU2005254616A1 (enExample) |
| CA (1) | CA2568575A1 (enExample) |
| ES (1) | ES2401110T3 (enExample) |
| GB (1) | GB0413688D0 (enExample) |
| WO (1) | WO2005123942A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005034628B4 (de) * | 2005-07-19 | 2007-08-23 | Epigenomics Ag | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA |
| EP1862555A1 (en) * | 2006-05-29 | 2007-12-05 | Klinikum der Universität Regensburg | Means and methods for diagnosing cancer or a corresponding predisposition |
| US20120196827A1 (en) * | 2006-06-12 | 2012-08-02 | Oncomethylome Sciences S.A. | Methylation markers for early detection and prognosis of colon cancers |
| AU2008316313B2 (en) * | 2007-10-23 | 2015-04-16 | Clinical Genomics Pty. Ltd. | A method of diagnosing neoplasms - II |
| JP2009247260A (ja) * | 2008-04-04 | 2009-10-29 | Sumitomo Chemical Co Ltd | Ｄｎａメチル化測定方法 |
| BRPI0924013A2 (pt) * | 2009-04-17 | 2015-11-24 | Hung-Cheng Lai | método para o exame de câncer |
| EP2529032B1 (en) * | 2010-01-26 | 2017-01-25 | Nipd Genetics Ltd | Methods and compositions for noninvasive prenatal diagnosis of fetal aneuploidies |
| US8278049B2 (en) | 2010-04-26 | 2012-10-02 | Ann & Robert H. Lurie Children's Hospital of Chicago | Selective enrichment of CpG islands |
| US20120004132A1 (en) * | 2010-07-02 | 2012-01-05 | Affymetrix, Inc. | Detection of Nucleic Acids and Proteins |
| JP5916058B2 (ja) * | 2011-08-26 | 2016-05-11 | 国立大学法人東北大学 | 細胞ストレス状態のバイオマーカー |
| US11021703B2 (en) | 2012-02-16 | 2021-06-01 | Cornell University | Methods and kit for characterizing the modified base status of a transcriptome |
| WO2015025864A1 (ja) * | 2013-08-21 | 2015-02-26 | 富士レビオ株式会社 | 吸収剤ポリヌクレオチドを用いた修飾核酸塩基の測定方法およびそのキット |
| ES2790533T3 (es) | 2015-05-22 | 2020-10-28 | Nipd Genetics Public Company Ltd | Análisis paralelo múltiplex de regiones genómicas blanco para análisis prenatales no invasivos |
| KR101735415B1 (ko) * | 2015-07-31 | 2017-05-16 | 한국과학기술연구원 | 헥산알 노출 특이적 메틸화 마커 유전자 및 이를 이용한 확인 방법 |
| JP6900325B2 (ja) * | 2016-01-27 | 2021-07-07 | 住友化学株式会社 | センサーチップ及びセンシングシステム |
| US10975417B2 (en) | 2016-02-23 | 2021-04-13 | Dovetail Genomics, Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
| EP3606550A2 (en) | 2017-04-03 | 2020-02-12 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| TW201930340A (zh) | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| SG11202012653XA (en) | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654183A (en) * | 1992-07-27 | 1997-08-05 | California Institute Of Technology | Genetically engineered mammalian neural crest stem cells |
| US5518901A (en) * | 1993-04-19 | 1996-05-21 | Murtagh; James J. | Methods for adapting nucleic acid for detection, sequencing, and cloning using exonuclease |
| US5714325A (en) * | 1993-09-24 | 1998-02-03 | New England Medical Center Hospitals | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood |
| US5866323A (en) * | 1995-04-07 | 1999-02-02 | Case Western Reserve University | Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors |
| AU7829398A (en) * | 1997-06-09 | 1998-12-30 | University Of Southern California | A cancer diagnostic method based upon dna methylation differences |
| US6337392B1 (en) * | 1998-05-07 | 2002-01-08 | The Rockefeller University | Lens transcriptional control elements and methods of use thereof |
| US6994971B1 (en) * | 1999-10-08 | 2006-02-07 | University Of Utah Research Foundation | Particle analysis assay for biomolecular quantification |
| AU784504B2 (en) * | 1999-11-19 | 2006-04-13 | Thomas V. Tittle | TR3-specific binding agents and methods for their use |
| AU2001271383B2 (en) * | 2000-06-23 | 2007-05-24 | The University Of Chicago | Methods for isolating centromere DNA |
| US20030157481A1 (en) * | 2001-12-10 | 2003-08-21 | Benjamin Thomas L. | Diagnosing and treating cancer cells using T-HR mutants and their targets |
| US20020197639A1 (en) * | 2001-06-08 | 2002-12-26 | Shia Michael A. | Methods and products for analyzing nucleic acids based on methylation status |
| AU2003206443A1 (en) * | 2002-02-20 | 2003-09-09 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Hedgehog-related prophylaxis, therapy and diagnosis of gi tract carcinogenesis |
| ATE335816T1 (de) * | 2002-09-18 | 2006-09-15 | Sirs Lab Gmbh | Verfahren zum nachweis prokaryontischer dna |
| AU2003900368A0 (en) * | 2003-01-24 | 2003-02-13 | Human Genetic Signatures Pty Ltd | Assay for nucleic acid molecules |
| JP3854943B2 (ja) * | 2003-05-23 | 2006-12-06 | 独立行政法人科学技術振興機構 | Ｄｎａメチル化率の測定方法 |
| EP1524523A1 (en) * | 2003-10-17 | 2005-04-20 | Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts | Use of ADAM 12 for diagnosis and therapy of preeclampsia |
| JP4688792B2 (ja) * | 2004-02-20 | 2011-05-25 | 独立行政法人科学技術振興機構 | Ｄｎａメチル化分析用ｄｎａアレイ及びその製造方法並びにｄｎａメチル化分析方法 |
-
2004
- 2004-06-18 GB GBGB0413688.3A patent/GB0413688D0/en not_active Ceased
-
2005
- 2005-03-03 JP JP2007515787A patent/JP2008502332A/ja active Pending
- 2005-03-03 ES ES05707697T patent/ES2401110T3/es not_active Expired - Lifetime
- 2005-03-03 US US11/571,026 patent/US20090270482A1/en not_active Abandoned
- 2005-03-03 CA CA002568575A patent/CA2568575A1/en not_active Abandoned
- 2005-03-03 EP EP05707697A patent/EP1761639B1/en not_active Expired - Lifetime
- 2005-03-03 WO PCT/EP2005/002251 patent/WO2005123942A2/en not_active Ceased
- 2005-03-03 AU AU2005254616A patent/AU2005254616A1/en not_active Abandoned
-
2009
- 2009-07-07 AU AU2009202745A patent/AU2009202745A1/en not_active Ceased
-
2012
- 2012-05-03 US US13/463,570 patent/US20120288509A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090270482A1 (en) | 2009-10-29 |
| JP2008502332A (ja) | 2008-01-31 |
| EP1761639A2 (en) | 2007-03-14 |
| AU2005254616A1 (en) | 2005-12-29 |
| CA2568575A1 (en) | 2005-12-29 |
| WO2005123942A2 (en) | 2005-12-29 |
| WO2005123942A3 (en) | 2006-04-13 |
| GB0413688D0 (en) | 2004-07-21 |
| EP1761639B1 (en) | 2013-01-02 |
| AU2009202745A1 (en) | 2009-07-30 |
| US20120288509A1 (en) | 2012-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120288509A1 (en) | Analysis of methylated nucleic acid | |
| Belk et al. | Epigenetic regulation of T cell exhaustion | |
| CN107586835B (zh) | 一种基于单链接头的下一代测序文库的构建方法及其应用 | |
| US20220205045A1 (en) | Raf1 fusions | |
| US20190389969A1 (en) | Ntrk2 fusions | |
| Casellas et al. | Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity | |
| US10246750B2 (en) | Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion | |
| CN102220412B (zh) | 用于检测甲基化dna的试剂盒和方法 | |
| Kao et al. | ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements | |
| JP6806668B2 (ja) | 核酸をプロービングおよびマッピングするためのｒｎａ誘導型システム | |
| US10370725B2 (en) | FGR fusions | |
| DK1566453T3 (en) | Qualitative differential splicing | |
| ES2667346T9 (es) | Estrategias de secuenciación de región genómica 3-D de interés | |
| WO2001066719A1 (fr) | Nouveau gene clone en neuroblastome humain et nouveaux fragments de gene | |
| KR101838394B1 (ko) | 뇌실하 영역의 돌연변이 유전자를 이용한 교모세포종 조직 기원의 예측 방법 및 동물 모델 | |
| Keuthan et al. | Alternative RNA splicing in the retina: insights and perspectives | |
| CN107922976A (zh) | 对聚腺苷二磷酸核糖聚合酶及端锚聚合酶双重抑制剂的灵敏度确定方法 | |
| AU2011203953B2 (en) | Analysis of methylated nucleic acid | |
| MacLennan et al. | How structural variation shapes the cancer epigenome | |
| Herbert | Endothelial cell gene expression | |
| Schrier | Regulation of Multiple Cellular Processes by the Long Noncoding RNA LINC00662 | |
| KR101760246B1 (ko) | 신규한 slco2b1 다형성 마커 및 이의 용도 | |
| Ye | Serial analysis of gene expression in human diseases | |
| Areshkov et al. | CHI3L1 and CHI3L2–one protein family, two opposite functions | |
| Yan | Deciphering the transcriptional regulation code in colorectal cancer genome |